Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 35 Biotech VC Funds in Norway

Last updated: Apr 2024 A list of 35 VC funds that invest in Biotech startups based in Norway. We rank investors based on the number of investments they made in Biotech companies from Norway. We update this investor list every month.

Top 35 Biotech VC Funds in Norway

Investor	Biotech Norway investments
Investinor	10
Birk Venture	5
SINTEF Venture AS	3
Hadean Ventures	3
Sarsia Seed Management	2
Meneldor	2
Innovations Kapital	1
Nordic Impact	1
Coalition for Epidemic Preparedness Innovations	1
World Wildlife Fund	1
Canica	1
Advent Life Sciences	1
Gezina	1
DNB	1
TeleVenture Management	1
SR One	1
Norselab	1
Skyfall Ventures	1
ProVenture	1
The Index Project	1
PAACS Invest AS	1
Advent Venture Partners	1
Forbion Capital Partners	1
Dynamk Capital	1
TD Veen	1
Protonic Partners	1
Bakken & Baeck	1
Glastad Invest	1
CoFounder	1
HealthCap	1
Teknoinvest	1
Sarsia	1
p53	1
Project Sandwater	1
Norwegian Research Council	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.

Investment focus

Software, Manufacturing, Biotechnology
Funding Round, Seed, Series A
Norway, United States, Switzerland

Portfolio highlights

Eyr — Eyr offers digital tools for medical consulting and doctor's prescription regarding various health issues.
Nomono — The Next Generation Audio company.
Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.

Birk Venture is a Scandinavian venture company exclusively focusing on the life science industry.

Investment focus

Biotechnology, Medical, Health Care
Seed, Series A, Funding Round
Norway, United Kingdom

Portfolio highlights

APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

SINTEF TTO & Venture invest in spin-off companies from SINTEF, NTNU and other research based institutions in Norway. Our dealflow reflect results from state-of-art research and cover a variety of sectors. SINTEF Venture seek to co-invest with VC funds with sector expertise at an early stage.

Investment focus

Manufacturing, Software, Energy
Seed, Funding Round, Pre-Seed
Norway, United States, United Kingdom

Portfolio highlights

Nomono — The Next Generation Audio company.
Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
KIT-AR — Reduce time and costs spent fixing errors on your manufacturing shopfloor with quality assurance and augmented reality- Click in to find how!

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Funding Round, Series B
Sweden, Norway, Austria

Portfolio highlights

Ribbon Biolabs — Ribbon Biolabs revolutionary technology for the fast and efficient automated synthesis of DNA is here to enable the new wave of biotechnological innovation.
Alex Therapeutics — The Alex DTx Platform enables partners within pharma and health care to effectively and reliably launch new DTx treatments by leveraging existing insights, modules, processes and data.
TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.

Sarsia Seed AS is a Norwegian Seed Capital Fund which invests in Norwegian early phase technology companies within the energy/cleantech and biotechnology/life science sectors.The fund has a total capital of 333.5 million NOK (approx, 40 mEUR/50 mUSD) and is managed by Sarsia Seed Management AS. The management company advises theFund board regarding investment decisions. The Fundâ€:tm:s duration is expected to be 12 (+3) years.The Management Teamâ€:tm:s strength lay in its competence, experience and extensive national and international network of industrial players and co-investors. The Teamâ€:tm:s collective experience comprises an optimal balance between operations, business and specialised technology know-how, applied research, and entrepreneurship; elements which are actively used both in the vetting and follow-up of investments.

Investment focus

Biotechnology, Finance, Therapeutics
Funding Round, Seed, Series A
Norway

Portfolio highlights

BerGenBio — BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
Sonoclear AS — BrainImage is the provider of SonoClear® - an acoustic coupling fluid for enhanced ultrasound imaging. This technology removes surgically induced image artefacts providing basis for enhanced clinical decision support.
Heimdall Power — Heimdall Power offers a rapid transition to fully digitized electric grid assets. Our technology increases on average the capacity of the grid by 30%.

Meneldor is a biopharmaceutical investment company .

Investment focus

Biotechnology, Health Care, Health Diagnostics
Series A, Seed, Debt Financing
Norway, Germany, United Kingdom

Portfolio highlights

Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.
Aptamer Group — Rapid Optimer development as antibody alternatives for therapeutic, drug delivery, diagnostics and bioprocessing.
Atriva Therapeutics — Therapies against viral infections. First-in-class host-targeting therapies to treat respiratory viral infections, including COVID-19 and influenza.

InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Series B, Series C
Sweden, Denmark, United States

Portfolio highlights

Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Action Pharma — Action Pharma A/S operates as a research and development focused biotechnology company. It discovers and develops new drugs and treatment concepts to treat cardiovascular disease and inflammatory diseases, as well as metabolic diseases, such as type-II diabetes and obesity. The company's product pipeline includes AP214, a modifiedÃMSH-peptide analogue for the treatment of post-surgical kidney injury associated with cardiac surgery; and AP1030 and AP11 series, oral anti-diabetic (OAD) for the treatment of type-II diabetes associated with overweight/obesity. Its product pipeline also comprise AP1189, an oral anti-inflammatory compound for the treatment of inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis; and AP405, a modified MSH peptide analogue for the treatment of inflammatory skin diseases, such as atopic dermatitis. The company was founded in 2000 and is based in Holte, Denmark.

Nordic Impact invests in, supports, and builds businesses and funds based around technology. The company's goal is to make impact investing mainstream and mobilize all business and capital towards solving the big problems in the world while making great financial returns.

Investment focus

Chemical, Life Science, Visual Search
Seed
Norway

Portfolio highlights

Iris.ai — Powerful Tools for Your Research. We have built a world-leading AI engine for scientific text understanding. Applied to literature reviews, data extraction, post-market surveillance or any other task involving thousands of documents like papers or patents, this engine will make your life a whole lot easier.

CEPI is a global partnership working to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Seed, Funding Round
United States, United Kingdom, India

Portfolio highlights

aVaxziPen — Thermally Stable Solid Dose Needle Free Vaccines
Aspen Pharmacare — Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets
NEC OncoImmunity AS — NEC OncoImmunity AS is an artificial intelligence (AI) driven biotech company offering proprietary machine-learning based software, which addresses the key knowledge gaps in the prediction of bona fide immunogenic antigens for personalized cancer immunotherapy and infectious disease vaccines.

World Wildlife Fund - The leading organization in wildlife conservation and endangered species. Learn how you can help WWF make a difference.

Investment focus

Seafood, Food Processing, Farming
Seed, Series A, Funding Round
Norway, Faroe Islands, United Kingdom

Portfolio highlights

OCEANIUM — Oceanium develop innovative, all-natural products from sustainably-sourced seaweed.
Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.

Canica is one of the largest privately owned investment companies in Norway. Our operations are focused on active, long-term ownership, primarily within sectors covering retail, fast moving consumer goods and real estate. Canica can offer core expertise within the fields of business development and finance, as well as capital and network in orderto create value and employment in a long-term perspective.

Investment focus

Beauty, Medical, Biotechnology
Private Equity, Series A, Series D
Norway, Denmark, Switzerland

Portfolio highlights

Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy' is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
Galecto — Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,

Investment focus

Biotechnology, Health Care, Medical
Series A, Funding Round, Series B
United States, United Kingdom, France

Portfolio highlights

Argá Medtech — Developing the next generation of Pulsed Field Ablation and Irreversible Electroporation Venture-capital backed company
PIC Therapeutics — PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.

Gezina

Investment focus

Health Care, Biotechnology, Clinical Trials
Funding Round
Norway

Portfolio highlights

SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.

DNB is a financial services group that offers financial services through mobile, online banking, bank offices, and international offices. The Group provides a full range of financial services, including loans, savings, advisory services, insurance, and pension products for retail and corporate customers. The company’s personal banking products andservices include savings and investment products.DNB offers its products and services to various sectors, including financial institutions, energy, manufacturing, healthcare, packaging, and forest products, shipping, offshore, and logistics, seafood, and telecom, media, and technology. They also distribute its products and services through its branches, in-store postal and banking outlets, and post office counters.DNB was founded in 1822 and is headquartered in Oslo, Norway.

Investment focus

Energy, Banking, Software
Funding Round, Seed, Post-IPO Debt
Norway, Sweden, Denmark

Portfolio highlights

Climeon — The Climeon Heat Power system, converts waste heat and geothermal heat into clean electricity. Saving fuel and electricity cost - as well as the environment.
Edify Energy — Edify Energy is a renewable energy company that specializes in solar project structuring, investments, and financing services.
Ocean GeoLoop — Ocean GeoLoop captures and stores or utilizes CO2 naturally. With no use of chemicals, toxins or other harmful consumables.

Making Venture Happen. Televenture is one of the leading venture capital companies in Norway.

Investment focus

Manufacturing, Software, Information Technology
Funding Round, Seed, Series A
Norway, United States

Portfolio highlights

CrayoNano — CrayoNano is a next generation semiconductor company. We specialize in nanotechnology that will enable a more sustainable and healthier life for tomorrow.
Genetic Analysis — Genetic Analysis AS (GA) has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances. By utilizing the DNA-based GA-map™ array technology, profiles of a patient’s gut microbiota is quickly generated and can be related to various health conditions. Genetic Analysis has developed a DNA-basedtechnology platform that allows for simultaneous analysis of a large number of similarities (but not identical) gene fragments in one reaction. The company’s focus is to utilize this technology platform to identify variations in the hundreds of different bacteria that exist in the gut (large and small intestine). The GA - map makes it possible, for the first time, to offer a diagnostic solution – including early detection - for many diseases that are affected by imbalances in the gut microbiota. Genetic Analysis will offer kits and services for a wide range of applications.
Stingray Marine Solutions — Stingray Marine Solutions is a Norwegian technology firm that produces a laser unit which, when lowered into salmon farming pens, kills sea lice. It is based on entrepreneur Esben Beck’s patented idea in 2010 for salmon louse removal using camera vision and laser. It all started with Esben Beck and a lathe in his basement in 1999. After more than10 years of deliveries to oil, gas and offshore companies, he decided to invest in his own products. He decided to found and develop his own salmon louse project, where design, production, software development, testing, and installation were carried out by using in-house resources.Stingray is based in Oslo, Norway.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Avalyn Pharma — This does NOT display on the home page
Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases

Norselab is a leading European impact investment house. We are dedicated to proving that impact is the future of investing across asset classes.

Investment focus

Software, SaaS, Agriculture
Seed, Funding Round, Series A
Norway, Switzerland, United States

Portfolio highlights

Beefutures — Beefutures combines biotechnology and data science and develops beekeeping tools. Our approach is to improve bee health and safety first and further optimise beekeeping operations and economics with digital tools.
imove — Een abonnement op een auto geeft je dezelfde vrijheid als autobezit. Je kan er in rijden zoveel en zo ver je maar wilt. Bij imove heb je na de minimaal gekozen contractduur de vrijheid om je abonnement op te zeggen wanneer je maar wilt. Je hoeft je geen zorgen te maken over onverwachte kosten of waardeverlies. Die stress is voor ons. Onze abonnementen zijn all-inclusive, met als resultaat: een waanzinnig comfort, exclusief voor jou.
Wanda — Wanda.space is a technology and logistics start-up delivering space as a service.

We are an early stage venture capital firm based in Oslo, Norway.

Investment focus

Software, Information Technology, Artificial Intelligence
Pre-Seed, Seed, Funding Round
Norway, Denmark, United States

Portfolio highlights

Januar — Innovative EU crypto companies use Januar's payment account solutions to accept payments & send payout's while maintaining full compliance & stable business operations.
Deckmatch — Tooling to drink from the firehose of data, that is your top of funnel (TOFU)
Databutton — Databutton is an online app builder that empowers the next generation of entrepreneurs and innovators. It enables anyone to create dynamic online apps in minutes by connecting to a growing array of sources, models, and integrations, or by utilizing their own datasets. 먹튀검증 https://muktts.net/

ProVenture invest in young digital technology startups in Norway. ProVenture have three seed funds and more than a billion NOK under management. ProVenture is a member of Norwegian Venture Association (NVCA).

Investment focus

Software, Oil and Gas, Information Technology
Seed, Funding Round, Series A
Norway, United States, India

Portfolio highlights

InfoTiles — InfoTiles provides real-time analytics solutions for Digital Water that span the water value chain, from supply & consumption to wastewater treatment and surveillance of waterways. InfoTiles unlocks data-driven planning, operations and maintenance.InfoTiles simplifies and automates the tedious steps of consolidating data, applying real-timeanalytics and machine learning so water utilities can turn insights into actions and benefit from more efficient, sustainable operations.
Wanda — Wanda.space is a technology and logistics start-up delivering space as a service.
Cimon Medical — Cimon Medical develops and manufactures novel Doppler ultrasound technology for healthcare and aim to become the market leader in continuous direct monitoring of blood-flow. The first product to be released in Q4 21 is NeoDoppler - non-invasive continuous monitoring of blood-flow in the brain of premature or critically ill infants.

Design to improve life is about solving real problems, small and large, simple and complex, systemic and emerging and is a life-long pursuit. The Index Project is a call to action. Are you in?

Investment focus

Artificial Intelligence, Chemical, SaaS
Seed, Series A, Series B
United States, Denmark, Chile

Portfolio highlights

Agribuddy — Management of agricultural support application "AGRIBUDDY".
CanopyLAB — The Future of Learning. Delivered Today.
Destácame — Destacame is the first behavior-based credit score in Latin America.

PAACS Invest is a privately owned Norwegian investment firm that focuses on active investments in healthcare and technology with a focus on sustainability.

Investment focus

Consulting, Health Care, Biotechnology
Seed
Norway

Portfolio highlights

Hemispherian — Hemispherian is an innovative preclinical pharmaceutical company focused on developing a novel class of small molecule drugs. These drugs target the TET2 enzyme as an epigenetic therapy for particularly aggressive cancers.

Advent Venture Partners is one of Europe's most successful growth and venture capital investors in market-leading tech and life sciences businesses. They have designed their strategy, teams and funds so they can focus on backing a select few companies. They pride their selves on establishing true partnerships with entrepreneurs in order tobuild valuable businesses together.

Investment focus

Biotechnology, Health Care, Software
Series B, Series A, Funding Round
United Kingdom, United States, Switzerland

Portfolio highlights

Wiz — Organizations of all sizes and industries use Wiz to rapidly identify and remove the most critical risks in AWS, Azure, GCP, and Kubernetes so they can build faster and more securely.
WorldStores — Established in 2008, Worldstores is now the UK’s largest online home & garden retailer. Offering unparalleled choice, value for money, customer service and a range of convenient delivery options, Worldstores is renowned as one of the UK's most exciting e-commerce success stories.ACHICA, the luxury flash-sale business, and baby specialistKiddicare also form part of the Worldstores Group and play a key part in the ambitious plans for Worldstores Group in becoming a household name in the home and garden market.
Acutus Medical — Acutus Medical develops medical technologies to treat complex cardiac arrhythmia. The company's platform displays the heart’s true activation pattern, turning the chaos of a complex arrhythmia into a clear vision for electrophysiologists.Acutus Medical is a privately funded company founded in 2011 and based in Carlsbad, California. Itsproducts are co-developed in the U.S. and Europe with an exceptional team of medical scientists, biomedical engineers, and other professionals.It was founded in 2011 and headquartered in Carlsbad, California.

Impacting the future of medicine.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, United Kingdom, The Netherlands

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
Orbis Medicines — Orbis Medicines is a novel macrocyclic chemistry and computational platform for high-throughput drug discovery.

Dynamk Capital is a New York headquartered growth equity and venture capital firm investing in life science industrials: tools, technologies and services that are critical for the discovery, development and production of life-saving therapies. Venture capital for Life Science tools.

Investment focus

Biotechnology, Medical, Health Care
Series A, Seed, Series B
United States, Canada, Norway

Portfolio highlights

CellFE — We transform the way gene therapies are manufactured to enable affordable advanced treatments for all.
Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

TD Veen is concerned with sustainable social development. Their contribution is to invest in companies and solutions that are good for both owners and society at large. The foundation of TD Veen is job satisfaction, creativity and a strong determination to invest in the very best people.At one stage they saw sense in targeting the investmentprofile, which also gave us a new perspective on the demand for returns and the role of investors. As a financial owner, they want to establish a healthy attitude toward results and returns. In companies where value is created over time.A differentiated portfolio is important to us. That is why they work with investments in new industries, such as e.g. health, or in parts of the world where they have not been before. Despite their Stavanger address, they want to invest outside of the petroleum sector.TD Veen has for many years supported the work of SOS Children’s Villages, including the project The Long Run, where they renovated old children’s villages in Romania and Lebanon. They have also contributed to starting up a separate pioneer project for foster families in Murmansk. Going ahead, they will to a greater degree also contribute to society at home, by building up a community of social entrepreneurs in Eiganesveien 95.

Investment focus

Software, Internet, Video Streaming
Funding Round, Seed, Series A
Norway, United Kingdom, Germany

Portfolio highlights

Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.
Dagens — Together with farmers and chefs, we co-create a transparent and resilient food system for the future. The farmers get a bigger part of the profit. Buyers get easy access to unique, biodiverse produce at competitive prices.
Atlas Metrics — The single source of truth for your ESG data

Protonic Partners is an investment firm.

Investment focus

SaaS, Biometrics, Information Services
Seed
Norway

Portfolio highlights

Mobai — Provider of attack detection, image manipulation detection and authentication. Strong and successful research team on biometrics.

A technology-driven design studio. Building digital products, brands and businesses, we help ambitious companies identify, explore and respond to new opportunities.

Investment focus

Chemical, Software, Life Science
Seed, Angel
Norway

Portfolio highlights

Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
Iris.ai — Powerful Tools for Your Research. We have built a world-leading AI engine for scientific text understanding. Applied to literature reviews, data extraction, post-market surveillance or any other task involving thousands of documents like papers or patents, this engine will make your life a whole lot easier.

Glastad Holding is a family-owned company whose roots can be traced back to the shipping industry in the early 20th century. Today, Glastad Holding is a thriving investment company with three subsidiaries: Glastad Farsund - real estate, Mosvolds Rederi - shipping, and Glastad Invest - private equity and listed investments. Glastad Holding aims toexert active and long term ownership.

Investment focus

Health Care, Biotechnology, Clinical Trials
Funding Round
Norway

Portfolio highlights

SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.

CoFounder is a management and investment company for technology companies with great growth potential. They are experienced entrepreneurs and business developers who provide management resources and early-stage capital. They work with spin-offs from both research and industrial environments, as well as standalone entrepreneurial companies.

Investment focus

Manufacturing, Industrial, SaaS
Funding Round, Seed, Series A
Norway

Portfolio highlights

AlumatIQ — AlumatIQ specializes in industrial robotics, automation, and digitalization in the aluminum industry. Their first product is robotic automation of the anode change process, with high accuracy, consistency, and speed. Improves health and safety conditions for operators in pot rooms and reduces emissions of HF and greenhouse gases.
Nicoustic — Nicoustic developed accurate, non-intrusive technology for separator-level measurement based on Guided Ultrasonic Waves. Their technique uses guided ultrasonic waves to measure the amounts of solids and liquids using sensors. It is being developed to measure the interface layers between emulsion and foam.Nicoustic's prototype is the outcomeof 20 years of study at the German Fraunhofer IKTS and a response to a challenge put forth by Equinor, the largest energy company in Norway.
Aviant — Delivering full-stack drone services that enables autonomous and on-demand transport of cargo.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United States, Sweden, France

Portfolio highlights

ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VCÂ´s in Scandinaviaaccording to track record of value created for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Funding Round, Series A
Sweden, Norway, United States

Portfolio highlights

GLO — glō is a venture-backed company focused on the development and commercialization of advanced LED display products using nanotechnology. The unique nanotechnology is based on 11 years of research at Lund University’s Nanometer Structure Consortium. Headed by Professor Lars Samuelson, one of the world’s leading scientists in this field, who haspublished more than 500 papers related to this technology.glō's first office is in Lund, Sweden, where basic material research continues for the next generation nanotechnology. glō's research and product development along with pilot fabrication operation is carried out at glō-USA in Sunnyvale, California. In 2016, glō established an Asia office in Taipei, Taiwan, one of the largest and fastest-growing regions for LED lighting and display applications.glō's technology sidesteps the technical limitations of current planar LED technology. It allows for the creation of highly efficient, stable and ultimately unique red, green, blue (RGB) emitters out of one material system. It aims to achieve the industry’s best color stability and ultimately enables the growth of red, green and blue emitters on the same wafer. Highly-efficient white LEDs with high color rendering will be possible without the need for phosphor conversion. It is the next enabling technology for advanced display, illumination and automotive applications.glō nanowire light-emitting diodes (nLEDs) are based on its proprietary hetero-structured semiconductor nanowire epitaxial growth and process technologies for which standard manufacturing equipment and materials can be utilized.glō currently holds over 175 patents across US, Europe and Asia. These patents are not subject to any cross-licensing with the LED oligopoly. The glō team is constantly strengthening its intellectual property position in this technology and related applications.
SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The companyâ€™s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the companyâ€™s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
Sol Voltaics — Founded in 2007, Sol Voltaics AB is a venture-backed, development-stage nanotechnology company focused on development and commercialization of highly efficient, third-generation photovoltaic concentrator solar cells based on its proprietary heterostructured nanowire epitaxial growth and process technologies.

Sarsia is an early-stage venture capital investor that invest in science-based technology companies. It was founded in 2006 and is located in Bergen, Hordaland.

Investment focus

Biotechnology, Pharmaceutical
Series A
Norway

Portfolio highlights

Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.

p53 identifies and invests in innovative healthcare companies, particularly in the fields of biotechnology and medical devices.

Investment focus

Medical, Life Science, Biotechnology
Series A
Denmark

Portfolio highlights

Calluna Pharma — Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.

Project Sandwater is a fresh take on venture investments within the Nordics and beyond.

Investment focus

Medical, Consulting, Life Science
Series A
Norway, The Netherlands

Portfolio highlights

Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

The Norwegian Research Council is the government's central research advisor. In 2012, the Research Council researched with more than 7 billion. This represents about 30% of R & D funding in the state budget.

Investment focus

Information Technology, Health Care, Biotechnology
Grant, Funding Round, Seed
Norway, Sweden

Portfolio highlights

CrayoNano — CrayoNano is a next generation semiconductor company. We specialize in nanotechnology that will enable a more sustainable and healthier life for tomorrow.
Elkem — Elkem is one of the world’s leading companies in the environmentally responsible manufacture of silicones, silicon and carbon based materials.
Aqualung Carbon Capture — Aqualung Carbon Capture provides industrial scale carbon capture units to speed up decarbonisation and mitigate carbon emissions.

Investors by industry

Media (entertainment)

EdTech

Consumer

Climate